ReviewFrontiers in endocrinology2022
Metabolomics of various samples advancing biomarker discovery and pathogenesis elucidation for diabetic retinopathy.
Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06914778 (Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales), which is not on this map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales
Who cites it
34 citing papers in PubMed, 56 citations in OpenAlex.
- L-Threonic Acid Inhibits Pathological Retinal Neovascularization by Modulation of CCL3-CCR5 Signaling Pathway.Investigative ophthalmology & visual science · 2026Article
- Impaired P4HA1-Driven Hydroxyproline Formation Mediates Scleral Collagen Disruption in Form-Deprivation Myopia.Investigative ophthalmology & visual science · 2026Article
- ComparativeMagnetic resonance in chemistry : MRC · 2026Article
- Metabolic Dysfunction and Inflammation in Diabetic Retinopathy: Insights From Metabolomics and Cytokine Analysis.Mediators of inflammation · 2026Article
- Mechanisms and applications of natural plant ingredients in modulating amino acid metabolism for the improvement of diabetic retinopathy: a review.Frontiers in endocrinology · 2026Review
- Development and Novel Therapeutics in Diabetic Retinopathy.Current diabetes reviews · 2026Review
- Oculomics: advances and perspectives from traditional Chinese medicine to modern multimodal biomarkers.International journal of ophthalmology · 2026Review
- Precision Medicine in Diabetic Retinopathy: The Role of Genetic and Epigenetic Biomarkers.Journal of clinical medicine · 2025Review
- Wogonin improves high glucose-induced ARPE-19 cell damage by inhibiting ferroptosis via suppressing the cGAS-STING pathway.In vitro cellular & developmental biology. Animal · 2025Article
- Metabolic alterations in diabetic patients: aqueous humor profiling for biomarker discovery.Amino acids · 2025Article
- The Causal Relationship and Association between Biomarkers, Dietary Intake, and Diabetic Retinopathy: Insights from Mendelian Randomization and Cross-Sectional Study.Diabetes & metabolism journal · 2025Article
- Tear lactate improves the evaluation of proliferative diabetic retinopathy in type-2 diabetes patients.Molecular biomedicine · 2025Article
- DNA-PKcs-Driven YAP1 Phosphorylation and Nuclear Translocation: a Key Regulator of Ferroptosis in Hyperglycemia-Induced Cardiac Dysfunction in Type 1 Diabetes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Recent Advancements in Understanding the Role and Mechanisms of Angiopoietin-like Proteins in Diabetic Retinopathy.Metabolites · 2025Review
- DNA hypermethylation of PLTP mediated by DNMT3B aggravates vascular dysfunction in diabetic retinopathy via the AKT/GSK3β signaling pathway.Clinical epigenetics · 2025Article
- Retinal Biomarkers in Diabetic Retinopathy: From Early Detection to Personalized Treatment.Journal of clinical medicine · 2025Review
- Targeting microRNAs in diabetic retinopathy: from pathogenic mechanisms to therapeutic potentials.Frontiers in endocrinology · 2025Review
- Editorial: Personalized medicine of diabetes retinopathy: from bench to bedside.Frontiers in endocrinology · 2025Article
- The immune-related plasma protein LAT2 as a protective modulator in diabetic retinopathy: a Mendelian randomization study.Frontiers in endocrinology · 2025Article
- Serum metabolomics signature of maternally inherited diabetes and deafness by gas chromatography-time of flight mass spectrometry.Journal of diabetes investigation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR) is a universal microvascular complication of diabetes mellitus (DM), which is the main reason for global sight damage/loss in middle-aged and/or older people. Current clinical analyses, like hemoglobin A1c, possess some importance as prognostic indicators for DR severity, but no effective circulating biomarkers are used for DR in the clinic currently, and studies on the latent pathophysiology remain lacking. Recent developments in omics, especially metabolomics, continue to disclose novel potential biomarkers in several fields, including but not limited to DR. Therefore, based on the overview of metabolomics, we reviewed progress in analytical technology of metabolomics, the prominent roles and the current status of biomarkers in DR, and the update of potential biomarkers in various DR-related samples
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.